GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entheon Biomedical Corp (XCNQ:ENBI) » Definitions » Current Ratio

Entheon Biomedical (XCNQ:ENBI) Current Ratio : 4.66 (As of Nov. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Entheon Biomedical Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Entheon Biomedical's current ratio for the quarter that ended in Nov. 2023 was 4.66.

Entheon Biomedical has a current ratio of 4.66. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for Entheon Biomedical's Current Ratio or its related term are showing as below:

XCNQ:ENBI' s Current Ratio Range Over the Past 10 Years
Min: 1.19   Med: 4.66   Max: 41.36
Current: 4.66

During the past 7 years, Entheon Biomedical's highest Current Ratio was 41.36. The lowest was 1.19. And the median was 4.66.

XCNQ:ENBI's Current Ratio is ranked better than
58.87% of 1556 companies
in the Biotechnology industry
Industry Median: 3.71 vs XCNQ:ENBI: 4.66

Entheon Biomedical Current Ratio Historical Data

The historical data trend for Entheon Biomedical's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entheon Biomedical Current Ratio Chart

Entheon Biomedical Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Nov21 Nov22 Nov23
Current Ratio
Get a 7-Day Free Trial 34.62 41.36 3.46 4.80 4.66

Entheon Biomedical Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.80 4.28 6.17 10.02 4.66

Competitive Comparison of Entheon Biomedical's Current Ratio

For the Biotechnology subindustry, Entheon Biomedical's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Entheon Biomedical's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entheon Biomedical's Current Ratio distribution charts can be found below:

* The bar in red indicates where Entheon Biomedical's Current Ratio falls into.



Entheon Biomedical Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Entheon Biomedical's Current Ratio for the fiscal year that ended in Nov. 2023 is calculated as

Current Ratio (A: Nov. 2023 )=Total Current Assets (A: Nov. 2023 )/Total Current Liabilities (A: Nov. 2023 )
=0.396/0.085
=4.66

Entheon Biomedical's Current Ratio for the quarter that ended in Nov. 2023 is calculated as

Current Ratio (Q: Nov. 2023 )=Total Current Assets (Q: Nov. 2023 )/Total Current Liabilities (Q: Nov. 2023 )
=0.396/0.085
=4.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Entheon Biomedical  (XCNQ:ENBI) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Entheon Biomedical Current Ratio Related Terms

Thank you for viewing the detailed overview of Entheon Biomedical's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Entheon Biomedical (XCNQ:ENBI) Business Description

Traded in Other Exchanges
Address
999 West Broadway Street, Suite 720, Vancouver, BC, CAN, V5Z 1K5
Entheon Biomedical Corp is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (DMT Products) for the purposes of treating addiction and substance use disorders. Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics, and licensed psychiatrists in the United States, certain countries in the European Union, and throughout Canada.

Entheon Biomedical (XCNQ:ENBI) Headlines

No Headlines